Founded by physicians and engineers, MSInsight’s mission is to support oncologists in choosing the proper treatment for each cancer patient. The company develops diagnostic solutions to identify crucial information in patients’ DNA to predict the success of treatments. In particular, the company is revolutionizing the diagnosis of Microsatellite Instability (MSI), a DNA alteration that will give them access to immunotherapy if found in a patient. Thanks to 20 years of academic research from Inserm, AP-HP, and Sorbonne University, MSInsight aims to provide more accurate diagnoses to make this therapeutic avenue accessible. To know more
